What position does dr paul cox hold at neurocept and what are his responsibilities there?

1. Who Dr. Paul Alan Cox is — a scientist turned lab director

Paul Alan Cox is a long‑time ethnobotanist and academic who has led conservation and drug‑discovery efforts for decades; the biographical profile on Brain Chemistry Labs and related biographies document his academic background, conservation awards and a career that moved from university posts to running focused research programs ^{[2] [5]}. That background frames his role today as the public face and scientific leader of Brain Chemistry Labs ^{[2] [1]}.

2. Title and organizational home: Executive Director of Brain Chemistry Labs

The organization’s own materials and its news posts name Dr. Cox explicitly as Executive Director of Brain Chemistry Labs / The Institute for EthnoMedicine, and refer to his efforts to partner with diagnostic companies to commercialize tests — a direct statement of his organizational position ^[1]. The sources provided do not refer to “Neurocept” by name; available sources do not mention Neurocept (not found in current reporting).

3. Responsibilities stated in reporting: directing research and partnerships

Reporting and the lab’s news pages describe Dr. Cox as directing research into brain chemistry, ethnobotanical drug discovery, and diagnostic development. He is portrayed as setting research direction, running a small lab in Jackson Hole, Wyoming, and seeking partnerships to make diagnostic tests available to neurologists within an 18–24 month horizon as reported by the lab ^{[3] [1]}. CNN and other coverage characterize him and his team as pursuing a “radically different approach” to neurodegenerative disease research, which suggests he leads both conceptual strategy and hands‑on research activities ^{[4] [3]}.

4. What he is reported to work on: diagnostics and experimental therapeutics

Fortune and the lab’s own pages emphasize Cox’s focus on translational aims — pursuing treatments that might prevent Alzheimer’s, ALS and other neurodegenerative diseases, and pursuing diagnostic tests tied to his lab’s discoveries. Those accounts place him at the center of both preclinical discovery and early efforts to translate those discoveries into clinical tools ^{[3] [1] [4]}.

5. Limits of the available reporting and unanswered questions

The provided sources make clear Dr. Cox’s title and general responsibilities at Brain Chemistry Labs but they do not show a formal role at any company named Neurocept; available sources do not mention Neurocept (not found in current reporting). The sources also do not provide a job description, reporting lines, or detailed management structure for his role; they describe activities and ambitions but stop short of organizational specifics such as staff size, budget authority, or contractual responsibilities ^{[1] [3]}.

6. Competing perspectives and credibility context

Profiles and feature journalism portray Cox as an unconventional but driven scientist pursuing high‑risk translational work outside large pharmaceutical structures ^[3]. The lab’s own communications present an optimistic timetable for diagnostics and highlight his leadership role ^[1]. Those two vantage points—external journalism and in‑house promotion—are complementary but not identical: Fortune provides independent reporting on his ambitions and methods, while Brain Chemistry Labs frames goals and timetables more directly ^{[3] [1]}. Readers should note the potential institutional bias in the lab’s public statements.

7. Bottom line for your question

Based on the provided sources, Dr. Paul Alan Cox serves as Executive Director of Brain Chemistry Labs / The Institute for EthnoMedicine and is responsible for directing its ethnobotanical and neurodegenerative‑disease research programs and pursuing diagnostic and translational partnerships; none of the supplied sources link him to Neurocept ^{[1] [3]}.